The trademark FYMOBRI was filed by Clementia Pharmaceuticals Inc., a corporation established under the laws of Canada (the "Applicant"). The application was published for oppositions on July 25, 2022, and received one opposition filed on September 22, 2022 by TAIHO PHARMACEUTICAL CO., LTD. on Likelihood of confusion. the opponent was represented by BALDER IP LAW, S.L. and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued September 22, 2022
The application was filed in English, and English was also language of all opposition proceedings (French was selected as the second language).